Status:
RECRUITING
ONO-4538 Study in Patients With Richter's Transformation
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Conditions:
Richter's Transformation
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Investigate the efficacy and safety of ONO-4538 in patients with Richter's transformation
Eligibility Criteria
Inclusion
- Histological diagnosis of diffuse large B-cell lymphoma (DLBCL)-type or Hodgkin lymphoma(HL)-type Richter's transformation with a history of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
- In the case of DLBCL-type Richter's transformation, refractory, intolerant or ineligible for treatment of DLBCL
- Patients with measurable disease
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Expected to survive for 90 days or more
Exclusion
- Serious complications
- Active multiple cancers
- Active central nervous system (CNS) disease
- History of allogeneic hematopoietic stem cell transplantation
Key Trial Info
Start Date :
November 19 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2030
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT06936943
Start Date
November 19 2025
End Date
July 31 2030
Last Update
December 23 2025
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Aichi Cancer Center
Nagoya, Aichi-ken, Japan
2
Kyusyu University Hospital
Fukuoka, Fukuoka, Japan, 812-8582
3
Hokkaido University Hospital
Sapporo, Hokkaido, Japan, 060-8648
4
Kyoto University Hospital
Kyoto, Kyoto, Japan